Wir sind mit live! Mehr erfahren
BIB-Symbol

ProShares Ultra NASDAQ Biotechnology

105,10 USD
-6,01
5,41 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
1 Tag
-5,41 %
5 Tage
-4,99 %
1 Monat
-3,57 %
3 Monate
5,35 %
6 Monate
21,19 %
Seit Jahresbeginn
31,97 %
1 Jahr
58,74 %
5 Jahre
21,08 %
10 Jahre
157,53 %

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %
Neutral
Seeking Alpha
vor 5 Monaten
Medical Technology Stocks: Innovation Endures As Valuations Reset
Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.
Medical Technology Stocks: Innovation Endures As Valuations Reset
Positiv
Seeking Alpha
vor 11 Monaten
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
Positiv
Seeking Alpha
vor 11 Monaten
BIB: A Tactical 2 X Leveraged Biotech ETF
BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps difference largely from borrowing and rebate adjustments. Designed for tactical investors, contrasting with MPT's long-term strategic approach assuming market efficiency.
BIB: A Tactical 2 X Leveraged Biotech ETF
Negativ
Investors Business Daily
letztes Jahr
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.
Pharma Tariffs Back In Spotlight On New Trump Threat
Neutral
Investors Business Daily
letztes Jahr
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
Negativ
Investors Business Daily
letztes Jahr
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
Neutral
Seeking Alpha
letztes Jahr
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Neutral
Seeking Alpha
letztes Jahr
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Neutral
Seeking Alpha
vor 2 Jahren
Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?
All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q2 season, nearly 2,500 companies are set to report.
Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?
Positiv
InvestorPlace
vor 2 Jahren
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom.  On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
Kursdiagramme mit Lightweight Charts™ umgesetzt